Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. AXS-05 is an oral, investigational NMDA receptor antagonist with multimodal activity under development for the treatment of Alzheimer's disease agitation (AD agitation) and smoking cessation. AXS-07 is an oral, rapidly absorbed, multi-mechanistic, investigational medicine under development for the acute treatment of migraine.

Employees

816

Sector

Pharmaceuticals

Calendar

03-01 - Q4 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
09/12/25	145.22 $	-1.59%	439,938
08/12/25	147.56 $	-1.11%	631,396
05/12/25	149.22 $	+0.80%	492,343
04/12/25	148.04 $	+0.16%	358,673
03/12/25	147.81 $	+4.03%	616,863

Delayed Quote Nasdaq, December 09, 2025 at 09:00 pm

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

147.56USD

Average target price

179.74USD

Spread / Average Target

+21.81%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 21:00:00 09/12/2025 GMT			5-day change	1st Jan Change
145.22 ^USD	-1.59%		+2.20%	+71.63%

12-04	Axsome Therapeutics, Inc. Presents at Piper Sandler 37th Annual Healthcare Conference, Dec-03-2025 04:00 PM
11-11	Axsome Therapeutics, Inc. completed the acquisition of Baergic Bio, Inc. from Avenue Therapeutics, Inc..	CI

Capitalization	7.32B 6.29B 5.9B 5.5B 10.13B 658B 11B 68.43B 26.6B 312B 27.47B 26.89B 1,149B	P/E ratio 2025 *	-38.3x	P/E ratio 2026 *	287x
Enterprise value	7.23B 6.21B 5.83B 5.43B 10B 649B 10.86B 67.55B 26.25B 308B 27.12B 26.54B 1,134B	EV / Sales 2025 *	11.5x	EV / Sales 2026 *	7.28x
Free-Float	81.71%	Yield 2025 *	-	Yield 2026 *	-

12-04	Axsome Therapeutics, Inc. Presents at Piper Sandler 37th Annual Healthcare Conference, Dec-03-2025 04:00 PM
11-11	Axsome Therapeutics, Inc. completed the acquisition of Baergic Bio, Inc. from Avenue Therapeutics, Inc..	CI
11-06	Axsome Therapeutics Acquires Subtype Selective Gaba-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy from AstraZeneca AB	CI
11-06	Axsome Therapeutics acquires AZD7325, a selective GABA-A modulator for treatment of epilepsy	RE
11-06	Mizuho Lifts Price Target on Axsome Therapeutics to $202 From $200, Keeps Outperform Rating	MT
11-06	Axsome Therapeutics Insider Sold Shares Worth $21,815,669, According to a Recent SEC Filing	MT
11-05	Axsome Therapeutics, Inc. entered into stock purchase agreement to acquire Baergic Bio, Inc. from Avenue Therapeutics, Inc. for $83.3 million.	CI
11-04	B. Riley Adjusts Axsome Therapeutics Price Target to $184 From $179, Maintains Buy Rating	MT
11-04	RBC Raises Price Target on Axsome Therapeutics to $198 From $189, Keeps Outperform Rating	MT
11-03	Axsome Therapeutics, Inc., Q3 2025 Earnings Call, Nov 03, 2025
11-03	Axsome Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-03	Axsome Therapeutics Q3 Net Loss Narrows, Revenue Rises	MT
11-03	Earnings Flash (AXSM) Axsome Therapeutics Posts Q3 Net Loss $0.94 a Share, vs. FactSet Est of $0.82 Loss	MT

11-06	Mizuho Lifts Price Target on Axsome Therapeutics to $202 From $200, Keeps Outperform Rating	MT
11-04	B. Riley Adjusts Axsome Therapeutics Price Target to $184 From $179, Maintains Buy Rating	MT
11-04	RBC Raises Price Target on Axsome Therapeutics to $198 From $189, Keeps Outperform Rating	MT
10-01	B. Riley Initiates Axsome Therapeutics at Buy With $179 Price Target	MT
08-05	RBC Raises Price Target on Axsome Therapeutics to $189 From $184, Keeps Outperform Rating	MT

Axsome Therapeutics, Inc. Share Price

Equities

AXSM

US05464T1043

Pharmaceuticals

Valuation: Axsome Therapeutics, Inc.

Chart: Axsome Therapeutics, Inc.

Latest news: Axsome Therapeutics, Inc.

Last Transcript: Axsome Therapeutics, Inc.

Analysts' recommendations: Axsome Therapeutics, Inc.

Press Releases: Axsome Therapeutics, Inc.

News in other languages: Axsome Therapeutics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Axsome Therapeutics, Inc.

ETFs: Axsome Therapeutics, Inc.

Biopharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

11-20	Axsome Therapeutics to Participate in Upcoming Investor Conferences	GL
11-06	Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics	AQ
11-06	Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy	GL
11-06	Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy	AQ
11-03	Axsome Therapeutics : Third Quarter 2025 Corporate Presentation	PU

07/06/21	Biogen : s'envole après le feu vert de la FDA à son traitement contre la maladie d'Alzheimer
16/12/19	Dow Jones Industrial Average : Les valeurs à suivre à Wall Street
16/12/19	USA-Les valeurs à suivre à Wall Street (actualisé)

1 day	-1.59%
1 week	+2.20%
Current month	-4.15%
1 month	+5.12%
3 months	+15.55%
6 months	+32.17%
Current year	+71.63%

1 week	144	151.63
1 month	136	152.94
Current year	79.19	152.94
1 year	75.56	152.94
3 years	53.71	152.94
5 years	19.38	152.94
10 years	1.94	152.94

Manager	Title	Age	Since
Herriott Tabuteau CEO	Chief Executive Officer	56	11/01/2012
Nick Pizzie DFI	Director of Finance/CFO	50	15/05/2018
Mark Jacobson COO	Chief Operating Officer	41	31/03/2014

Director	Title	Age	Since
Herriott Tabuteau CHM	Chairman	56	11/01/2012
Roger Jeffs BRD	Director/Board Member	63	30/11/2014
Mark Coleman BRD	Director/Board Member	57	30/11/2014

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
AXSOME THERAPEUTICS, INC.	-1.59%	+2.20%	+45.57%	+93.99%	7.44B
REGENERON PHARMACEUTICALS, INC.	-1.52%	-6.66%	-12.11%	-7.66%	72.15B
CSL LIMITED	-0.71%	-0.96%	-35.98%	-39.45%	59.28B
UCB	-2.42%	-0.33%	+33.08%	+237.98%	54.78B
SAMSUNG BIOLOGICS CO.,LTD.	+1.90%	+66.00%	+66.00%	+66.00%	51.37B
BIOGEN INC.	-2.55%	-2.41%	+12.39%	-38.38%	26.47B
INCYTE CORPORATION	-1.59%	-6.19%	+31.97%	+15.57%	18.98B
INNOVENT BIOLOGICS, INC.	-0.77%	-8.77%	+119.53%	+161.72%	18.86B
ALTEOGEN INC.	-0.22%	-12.28%	+60.35%	+1,013.28%	16.69B
BRIDGEBIO PHARMA, INC.	-3.46%	+0.29%	+142.95%	+706.19%	14.31B
Average	-0.68%	-3.39%	+46.37%	+220.92%	34.03B
Weighted average by Cap.	-0.52%	-2.86%	+25.79%	+128.04%

	2025 *	2026 *
Net sales	630M 541M 508M 473M 872M 56.62B 947M 5.89B 2.29B 26.84B 2.36B 2.31B 98.87B	979M 841M 789M 735M 1.35B 87.95B 1.47B 9.15B 3.56B 41.69B 3.67B 3.6B 154B
Net income	-188M -162M -152M -141M -260M -16.9B -283M -1.76B -683M -8.01B -706M -691M -29.51B	22.58M 19.4M 18.2M 16.96M 31.23M 2.03B 33.94M 211M 82.04M 962M 84.74M 82.94M 3.54B
Net Debt	-94.35M -81.07M -76.06M -70.87M -131M -8.48B -142M -882M -343M -4.02B -354M -347M -14.81B	-199M -171M -161M -150M -276M -17.9B -299M -1.86B -724M -8.49B -748M -732M -31.26B